Paul Berns
SelectiveNamed in filings at ARCH Venture PartnersOn the current fund
- Board seats filed
- 8
Named in filings at ARCH Venture PartnersOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Ollin Biosciences | Biotech & pharma | May 2026 | Vida Ventures |
| Metsera | Biotech & pharma | November 2024 | None on file |
| Mirador Therapeutics | Biotech & pharma | December 2023 | None on file |
| Elephas Biosciences | Biotech & pharma | August 2022 | None on file |
| Areteia Therapeutics | Biotech & pharma | June 2022 | Bain Capital Life Sciences |
| Neumora Therapeutics | Biotech & pharma | September 2020 | None on file |
| Unity Biotechnology | Biotech & pharma | October 2016 | None on file |
| Cellectar Biosciences | Biotech & pharma | August 2014 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Paul Berns on the board, based on 8 filed seats with a verified or cited source.